Drug maker Ranbaxy on Tuesday said it has temporarily suspended all raw material shipments from two facilities — Toansa and Dewas, to review “processes and controls”.
The announcement comes nearly a month after the US Food and Drug Administration prohibited import of products manufactured by Ranbaxy at its plant at Toansa. This was the company's fourth plant to face regulatory action from the US food regulator, after Mohali, Paonta Sahib and Dewas plants.
In a communication to the BSE, the Indian subsidiary of Japanese drug maker Daichii Sankyo said it “is currently examining processes and controls at all Company's Active Pharmaceutical Ingredients (API) manufacturing and quality units. This action has led to temporarily putting on hold shipments from Company's API facilities of the Toansa and Dewas Plants.”
According to experts, the suspension of shipments from the two plants is likely to hit supplies to various markets, including Europe and India.
Meanwhile, the company added this “voluntary decision was taken as a precautionary measure and out of abundant caution to better allow the company to assess and review the processes and controls”.
The company will resume shipments after reassuring them about the processes and controls at these facilities.
Besides, a ‘Quality & Integrity Committee’ has also been constituted to help and assure good governance to all Ranbaxy stakeholders.
“Its primary role is to provide oversight on the company's manufacturing and quality operations, systems, organization and integrity,” Ranbaxy said.
The company’s shares closed at Rs 367.05 apiece on the BSE, up 0.99 per cent from its previous close.
